Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clebopride vs placebo for suspected rumination syndrome (crossover)
2019-002185-13Phase 3Active
- Sponsor
- KU Leuven
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of clebopride in rumination disorder (2 arms), sponsored by KU Leuven. Primary endpoint: Overall treatment evaluation (OTE). Started Aug 2019; status: active.
02
Drugs
clebopride
03
Conditions
rumination disorder
Beyond the preview
Go deeper on 2019-002185-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002185-13.